Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA
Restricted accessResearch articleFirst published online October, 2016
Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA
We investigated the agreement between the tuberculin skin test (TST) and the QuantiFERON-TB gold (QFT-G) assay in the diagnosis of latent tuberculosis infection (LTBI) in patients with systemic lupus erythematosus (SLE). Furthermore, we evaluated the factors associated with indeterminate results in the QFT-G assay in patients with SLE.
Methods
We enrolled 136 patients with SLE prospectively, and compared them to 66 patients with rheumatoid arthritis (RA). In addition to the TST, QFT-G assay, patients’ medications, and Bacillus Calmette-Guérin (BCG) vaccination status were also investigated. A positive TST or QFT-G assay result without an active tuberculosis lesion on chest x-ray was considered to indicate a diagnosis of LTBI.
Results
The prevalence of LTBI was 26.5% in patients with SLE and 30.3% in patients with RA. The agreement between the TST and QFT-G assay was fair in SLE patients, but poor in RA patients. BCG vaccination was one factor associated with discordance between TST and QFT-G. Older age and higher SLE Disease Activity Index (SLEDAI) score were associated with a negative TST/positive QFT-G result in patients with SLE. Higher SLEDAI score and increased glucocorticoid dose were associated with an indeterminate result in the QFT-G assay for patients with SLE.
Conclusions
Agreement between the QFT-G assay and TST in patients with SLE was found to be fair. However, BCG vaccination status, age, and SLEDAI score are all factors that could result in discordance between the two tests. Indeterminate results from the QFT-G assay may be caused by a higher SLEDAI score or increased glucocorticoid dose.
KangIParkSH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol2003; 15: 528–534.
2.
DoriaACanovaMTononM, . Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev2008; 8: 24–28.
3.
WangZWangYZhuR, . Long-term survival and death causes of systemic lupus erythematosus in China: A systemic review of observational studies. Medicine (Baltimore)2015; 94: e794–e794.
4.
Zandman-GoddardGShoenfeldY. Infections and SLE. Autoimmunity2005; 38: 473–485.
5.
YunJELeeSWKimTH, . The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol2002; 20: 127–132.
6.
KimHAYooCDBaekHJ, . Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol1998; 16: 9–13.
7.
World Health Organization. Global tuberculosis control: Epidemiology, strategy, financing. WHO report, 2015. Geneva: World Health Organization.
8.
LalvaniAMillingtonKA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev2008; 8: 147–152.
9.
IldirimIHacimustafaogluMEdizB. Correlation of tuberculin induration with the number of Bacillus Calmette-Guerin vaccines. Pediatr Infect Dis J1995; 14: 1060–1063.
10.
FarhatMGreenawayCPaiM, . False-positive tuberculin skin tests: What is the absolute effect of BCG and non-tuberculous mycobacteria?Int J Tuberc Lung Dis2006; 10: 1192–1204.
11.
ChoiCMKangCIKimDH, . The role of TST in the diagnosis of latent tuberculosis infection among military personnel in South Korea. Int J Tuberc Lung Dis2006; 10: 1342–1346.
12.
WangLTurnerMOElwoodRK, . A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax2002; 57: 804–809.
13.
Ponce de LeonDAcevedo-VasquezESanchez-TorresA, . Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis. Ann Rheum Dis2005; 64: 1360–1361.
14.
Pascual-RamosVHernandez-CruzBVillalobosI, . Purified protein derivative reaction in systemic lupus erythematosus patients. Indirect study of cellular immunity. Lupus2002; 11: 25–30.
15.
MazurekGHJerebJVernonA, . Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep2010; 59(RR-5): 1–25.
16.
DielRGolettiDFerraraG, . Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: A systematic review and meta-analysis. Eur Respir J2011; 37: 88–99.
17.
KimJHChoSKHanM, . Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases. Semin Arthritis Rheum2013; 42: 424–432.
18.
LeeJHSohnHSChunJH, . Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls. Korean J Intern Med2014; 29: 76–84.
19.
YilmazNZehra AydinSInancN, . Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients. Lupus2012; 21: 491–495.
20.
Arenas Miras Mdel M, Hidalgo-Tenorio C, Jimenez-Gamiz P, et al. Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test. Biomed Res Int 2014; Article ID 291031.
21.
KangYALeeHWYoonHI, . Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA2005; 293: 2756–2761.
22.
TakedaNNojimaTTeraoC, . Interferon-gamma release assay for diagnosing Mycobacterium tuberculosis infections in patients with systemic lupus erythematosus. Lupus2011; 20: 792–800.
23.
JungHJKimTJKimHS, . Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases. Rheumatol Int2014; 34: 1711–1720.
24.
DielRLoddenkemperRNienhausA. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: A metaanalysis. Chest2010; 137: 952–968.
25.
TanEMCohenASFriesJF, . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
26.
ArnettFCEdworthySMBlochDA, . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988; 31: 315–324.
27.
SolovicISesterMGomez-ReinoJJ, . The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J2010; 36: 1185–1206.
28.
MazurekGHJerebJLobueP, . Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep2005; 54: 49–55.
29.
JungYJWooHIJeonK, . The significance of sensitive interferon gamma release assays for diagnosis of latent tuberculosis infection in patients receiving tumor necrosis factor-alpha antagonist therapy. PLoS One2015; 10: e0141033–e0141033.
30.
ChangBParkHYJeonK, . Interferon-gamma release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol2011; 30: 1535–1541.
31.
LeeHParkHYJeonK, . QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS One2015; 10: e0119260–e0119260.
Mehta B, Zapantis E, Petryna O, et al. Screening optimization of latent tuberculosis infection in rheumatoid arthritis patients. Arthritis 2015; Article ID 569620.
34.
KimEYLimJEJungJY, . Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis2009; 9: 207–207.
35.
TamboreneaMNTateGMyslerE, . Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int2010; 30: 613–616.
36.
LeeEHolzmanRS. Evolution and current use of the tuberculin test. Clin Infect Dis2002; 34: 365–370.
37.
BartalesiFVicidominiSGolettiD, . QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J2009; 33: 586–593.
38.
PrattANichollKKayL. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: The Newcastle (UK) experience. Rheumatology (Oxford)2007; 46: 1035–1036.
39.
MaedaTBannoSMaedaS, . Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: Proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Mod Rheumatol2010; 20: 18–23.
40.
BeharSMShinDSMaierA, . Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol2009; 36: 546–551.
41.
CobanogluNOzcelikUKalyoncuU, . Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis2007; 11: 1177–1182.
42.
La CavaA. Lupus and T cells. Lupus2009; 18: 196–201.
43.
HeroldMJMcPhersonKGReichardtHM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci2006; 63: 60–72.
